{'fraction_non_alphanumeric': 0.03565950920245399, 'fraction_numerical': 0.046012269938650305, 'mean_word_length': 5.167848699763593, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AB1407-HPR Adverse drug reactions in patients with rheumatoid arthritis

Background adverse drug reactions (ADRs) are events that may seriously affect the health of people who use drugs for therapeutic purposes.1 In the case of patients with rheumatic diseases the existence of comorbidities, the use of DMARDs, or polymedication may increase the risk of developing any type of adverse drug reaction.2 Objectives We aim to describe the adverse drug reactions in patients with rheumatoid arthritis. Methods A cross sectional study was performed during 2017; we collected data from the patients who reported an adverse drug reaction in the consult with a multidisciplinary health care team. We collected the ADR characteristics, medication group and severity. Descriptive epidemiology was done. Results A total of 6793 patients were diagnosed with rheumatoid arthritis and comorbidities in our specialised centre where 1.8% (123) patients reported any adverse drug reaction, 82% were women. The main diagnosis was rheumatoid arthritis 88% followed by rheumatoid arthritis plus osteoarthritis 12%; less than 1% was other diagnoses. The drug that had a higher proportion of ADRs was methotrexate 33% followed by leflunomide 14%, Certolizumab 7% and acetaminophen combined with hydrocodone 6%; see table 1. The dermatological adverse events were the most common followed by gastrointestinal events and errors in self-medication 11%, these adverse events were classified as mild or moderate; seeAbstract AB1407-HPR – Table 1 ADVERSE EVENT N % DERMATOLOGIC 31 25.2 GASTROINTESTINAL 20 16.26 SELF-MEDICATION 14 11.38 THERAPEUTIC FAILURE 10 8.13 PAIN 9 7.32 HEADACHE 8 6.5 BREATHING DIFFICULTY 7 5.69 GENERAL DISCOMFORT 5 4.07 DIZZINESS, DYSPNEA 4 3.25 HERPES ZOSTER -VIRUS 4 3.25 INFECTION 2 1.63 HAIR-LOSS 2 1.63 Conclusions The proportion of adverse events in our centre is low; other studies had shown, the frequency of patients with ADRs is common, mainly in patients who use anti rheumatic medications. This real life data can support the evidence for future studies in order to prevent ADRs. References [1] Machado-Alba JE, Ruiz AF, Machado-Duque ME. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Rev Panam Salud Publica. 2014;36(6):396–401. [2] Tragulpiankit P, Chulavatnatol S, Rerkpattanapipat T, Janwityanujit S, Somjarit S, Sirikhedgon U. Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients. International journal of rheumatic diseases. 2012;15(3):315–21. Disclosure of Interest None declared